Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors

Clinical trial NCT05511844 · TERMINATED

Trial details

NCT number: NCT05511844
Sponsor: Orum Therapeutics USA, Inc.
Status: TERMINATED
Phase: Phase 1
Study type: INTERVENTIONAL

HER2-positive Breast Cancer HER-2 Protein Overexpression HER-2 Gene Amplification HER2 Gene Mutation

Start date: 2022-10-03
Primary completion: 2025-06-02
Enrollment: 25

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.